natgillin/translations-raw huggingface dataset:
Ibandronic Acid Teva 50 mg is used to prevent ‘skeletal events’ (fractures [broken bones] or bone complications requiring treatment) in patients with breast cancer and bone metastases (when the cancer has spread to the bone).
Ibandronatna kiselina Teva koristi se za sprječavanje „koštanih poremećaja” (fraktura [prijeloma kostiju] ili koštanih komplikacija koje zahtijevaju liječenje) u bolesnika s rakom dojke i metastazama u kostima (ako se rak proširio u kosti).
Ibandronic Acid Teva 50 mg: Medicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2).
Ibandronatna kiselina Teva 50 mg: lijek se izdaje na ograničeni recept (vidjeti Dodatak I: Sažetak opisa svojstava lijeka, dio 4.2).
Ibandronic Acid Teva comes in blisters (PVC/Aclar/PVC – Aluminium) in cartons of 1 or 3 tablets.
Ibandronatna kiselina Teva dostupna je u pakovanju od 1 ili 3 tablete u PVC/Aclar/PVC //aluminij blisteru, u kutiji.
Ibandronic Acid Teva comes in blisters (PVC/Aclar/PVC – Aluminium) in cartons of 28 or 84 tablets.
Ibandronatna kiselina Teva dostupna je u pakovanju od 28 tableta ili 84 tablete u PVC/Aclar/PVC //aluminij blisteru, u kutiji.
Ibandronic Acid Teva is a ‘generic medicine’.
Ibandronatna kiselina Teva je „generički lijek”.
Ibandronic Acid Teva is less effective if it’s taken with food.
Ibandronatna kiselina Teva je manje učinkovita ako se uzme s hranom.
Ibandronic Acid Teva may also do so.
Ibandronatna kiselina Teva možu dovesti do jednake reakcije.
Ibandronic Acid Teva should not be used during breast-feeding.
Ibandronatna kiselina Teva ne smije se koristiti za vrijeme dojenja.
Ibandronic Acid Teva should not be used during lactation.
Ibandronatna kiselina Teva se ne smije koristiti za vrijeme dojenja.
Ibandronic Acid Teva should not be used in children and adolescents below the age of 18 years.
Ibandronatna kiselina Teva ne se smije davati djeci i adolescentima mlađima od 18 godina.
Ibandronic acid therapy should only be initiated by physicians experienced in the treatment of cancer.
Liječenje ibandronatnom kiselinom smiju započeti samo liječnici s iskustvom u liječenju raka.
Ibandronic acid was not studied in the paediatric population, therefore no efficacy or safety data are available for this patient population.
Ibandronatna kiselina nije ispitivana na pedijatrijskoj populaciji, stoga nisu dostupni podaci o djelotvornosti i sigurnosti primjene u ovoj skupini bolesnika.
Ibandronic acid was taken 60 minutes before the first food or drink of the day (post-dose fasting period).
60 minuta prije uzimanja prvog obroka ili pića (razdoblje gladovanja nakon doze).
Ibritumomab tiuxetan is a recombinant murine IgG1 kappa monoclonal antibody specific for the B- cell antigen CD20.
Ibritumomab tiuksetan rekombinantno je mišje IgG1 kapa-monoklonsko protutijelo specifično za B-stanični antigen CD20.
ibritumomab tiuxetan vial: sodium chloride, water for injections
bočica ibritumomab tiuksetana: natrijev klorid, voda za injekcije
Ibritumomab tiuxetan vial: type I glass vial with a rubber stopper (teflon-lined bromobutyl) containing 2 ml solution.
Bočica ibritumomab tiuksetana: staklena bočica tipa I s gumenim čepom (od bromobutila obloženog teflonom) koja sadrži 2 ml otopine.
Ibrutinib has minimal renal clearance; urinary excretion of metabolites is < 10% of the dose.
Ibrutinib ima minimalni bubrežni klirens; izlučivanje metabolita mokraćom je < 10% doze.
Ibrutinib has no genotoxic properties when tested in bacteria, mammalian cells or in mice.
Ibrutinib nema genotoksična svojstva kada se ispitivao na bakterijama, stanicama sisavaca ili miševima.
Ibrutinib is a P-gp and breast cancer resistance protein (BCRP) inhibitor in vitro.
Ibrutinib je inhibitor P-gp-a i proteina rezistencije raka dojke (engl. breast cancer resistance protein, BCRP) in vitro.
Ibrutinib is a potent, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK).
Ibrutinib je potentna, mala molekula, inhibitor Brutonove tirozin kinaze (BTK).
Ibrutinib is an in vitro inhibitor of P-gp and BCRP (see section 4.5).
Ibrutinib je in vitro inhibitor P- gp-a i BCRP-a (vidjeti dio 4.5).
Ibrutinib may also inhibit BCRP in the liver and increase the exposure of drugs that undergo BCRP-mediated hepatic efflux, such as rosuvastatin.
Ibrutinib također može inhibirati BCRP u jetri i povećati izloženost lijekovima koji prolaze kroz BCRP-om posredovani hepatički efluks, poput rosuvastatina.
ibuprofen ( used to treat fever, pain and some forms of inflamamtion),
ibuprofen (koristi se za liječenje vrućice, boli i nekih oblika upale),
Ibuprofen is a non selective inhibitor of cyclo- oxygenase, leading to reduced synthesis of prostaglandins.
Ibuprofen je neselektivni inhibitor ciklooksigenaze, s posljedičnom inhibicijom sinteze prostaglandina.
Ibuprofen may reduce the ability of your baby’s blood to clot.
Ibuprofen može poremetiti zgrušavanje krvi u Vašeg djeteta.
ibuprofen, diclofenac, ketorolac or other medicines - used to treat pain and swelling in arthritis and other illnesses
ibuprofen, diklofenak, ketorolak ili drugi lijekovi koji se koriste za liječenje boli i otoka kod artritisa i drugih bolesti
Ibutilide Sotalol (saquinavir/ritonavir)
Ibutilid Sotalol (sakvinavir/ritonavir)
Icandra 50 mg/850 mg film-coated tablets are yellow, oval tablets with “NVR” on one side and “SEH” on the other.
Icandra 50 mg/850 mg filmom obložene tablete su žute, ovalne tablete s oznakom „NVR” na jednoj strain i „SHE” na drugoj strani.
Icandra is available in packs containing 10, 30, 60, 120, 180 or 360 film-coated tablets and in multi- packs containing 120 (2x60), 180 (3x60) or 360 (6x60) film-coated tablets.
Icandra je dostupan u pakiranjima od 10, 30, 60, 120, 180 ili 360 filmom obloženih tableta i u višestrukim pakiranjima od 120 (2x60), 180 (3x60) ili 360 (6x60) filmom obloženih tableta.
Icandra is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled with metformin and a sulphonylurea.
Icandra je indiciran u kombinaciji sa sulfonilurejom (tj. trojna kombinirana terapija) kao dodatak dijeti i tjelovježbi u odraslih bolesnika u kojih je kontrola nedostatna s metforminom i sulfonilurejom.
Icandra is indicated in the treatment of adult patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.
Icandra je indiciran u liječenju odraslih bolesnika u kojih se ne može postići zadovoljavajuća kontrola glikemije primjenom oralnog metformina u maksimalno podnošljivoj dozi ili u bolesnika koji se već liječe kombinacijom odvojenih tableta vildagliptina i metformina.
Icandra is indicated in the treatment of type 2 diabetes mellitus:
Icandra je indiciran u liječenju šećerne bolesti tipa 2:
Icandra is indicated in triple combination therapy with insulin as an adjunct to diet and exercise to improve glycaemic control in adult patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.
Icandra je indiciran u trojnoj kombiniranoj terapiji sa inzulinom kao dodatak dijeti i tjelovježbi za poboljšanje kontrole glikemije u odraslih bolesnika u kojih stabilna doza inzulina i metformina ne omogućuju odgovarajuću kontrolu glikemije.
Icandra is used to treat adult patients with type 2 diabetes.
Icandra se primjenjuje za liječenje bolesnika sa šećernom bolešću tipa 2.
Icandra should not be used in patients with creatinine clearance < 60 ml/min (see sections 4.3, 4.4 and 5.2).
Icandra se ne smije primjenjivati u bolesnika s klirensom kreatinina <60 ml/min (vidjeti dijelove 4.3, 4.4 i 5.2).
Icatibant volume of distribution (Vss) is about 20-25 L. Plasma protein binding is 44%.
Volumen distribucije ikatibanta (Vss) iznosi oko20-25 L. Vezanje za proteine plazme iznosi 44%.
Icatibant was not teratogenic when administered by s.c. injection during early embryonic and fetal development in rat (top dose 25 mg/kg/day) and rabbit (top dose 10 mg/kg/day).
Ikatibant nije imao teratogeni učinak pri primjeni putem s.c. injekcije tijekom ranog embrionalnog i fetalnog razvoja kod štakora (najveća doza 25 mg/kg/dan) i kunića (najveća doza 10 mg/kg/dan).
icca syndrome (including dry eyes and dry mouth)
icca (suhi) sindrom (uključujući suhoću očiju i suhoću usta)
icca syndrome (including dry eyes and dry mouth);
icca (suhi) sindrom (uključujući suhoću očiju i suhoću usta),
Icepharm hf.,
Icepharma hf.,
ICH fatal
ICH sa smrtnim ishodom
ICH non-fatal
ICH bez smrtnog ishoda
ickle cell anaemia (an abnormality of red blood cells).
anemiju srpastih stanica (poremećaj crvenih krvnih stanica)
ickle cell anaemia (an abnormality of red blood cells).
anemiju srpastih stanica (poremećaj crvenih krvnih stanica).
ickle cell anaemia;
anemije srpastih stanica,
ickness (mild nausea) feeling of pins and needles (mild peripheral neuropathy)
osjećaj mučnine (blaga mučnina) osjećaj bockanja i iglica (blaga periferna neuropatija)
ickness,
mučnina,
ickness,
ustava
Iclusig 15 mg film-coated tablets Iclusig 30 mg film-coated tablets Iclusig 45 mg film-coated tablets ponatinib
Iclusig 15 mg filmom obložene tablete Iclusig 30 mg filmom obložene tablete Iclusig 45 mg filmom obložene tablete ponatinib
Iclusig 15 mg film-coated tablets ponatinib
Iclusig 15 mg filmom obložene tablete ponatinib
Iclusig 30 mg film-coated tablets ponatinib
Iclusig 30 mg filmom obložene tablete ponatinib
Iclusig 45 mg film-coated tablets ponatinib
Iclusig 45 mg filmom obložene tablete ponatinib
Iclusig can only be obtained with a prescription and treatment should be started by a doctor who is experienced in the diagnosis and treatment of leukaemia.
Iclusig se izdaje samo na liječnički recept, a liječenje treba započeti liječnik iskusan u dijagnosticiranju i liječenju leukemije.
Iclusig has been investigated in one main study involving 449 patients with CML or Ph+ ALL and who were intolerant or resistant to treatment with dasatinib or nilotinib, or had the T315I mutation.
Iclusig je ispitivan u jednom glavnom ispitivanju koje je uključivalo 449 bolesnika s KML-om ili ALL-om Ph+ i koji nisu podnosili liječenje ili nisu reagirali na liječenje dasatinibom odnosno nilotinibom ili su imali mutaciju T315I.
Iclusig is used in patients who cannot tolerate or do not respond to dasatinib or (for patients with CML) nilotinib, which are other cancer medicines of the same class, and in whom subsequent treatment with imatinib (a third such medicine) is not considered appropriate.
Iclusig se koristi u bolesnika koji ne podnose ili ne reagiraju na liječenje dasatinibom ili (za bolesnike s KML-om) nilotinibom, koji su drugi lijekovi istog razreda protiv raka i kod kojih se naknadno liječenje imatinibom (trećim takvim lijekom) ne smatra odgovarajućim.
Iclusig may be administered with or without food.
Iclusig se može uzeti s hranom ili bez nje.
Iclusig should be interrupted immediately in case of vascular occlusion.
U slučaju vaskularne okluzije liječenje Iclusigom mora se odmah prekinuti.
Iclusig with food and drink
Iclusig s hranom i pićem
ICRP-30 data
Podaci prema ICRP-30
IDA 8 mg/ m2 i.v. (0.5 h), days 7, 8, 14, 15; CP 500 mg/ m2 i.v.(1 h) day 1;
IDA 8 mg/m2 i.v. (0,5 h), dani 7, 8, 14, 15; CP 500 mg/m2 i.v.(1 h) dan 1;
IDA 8 mg/m2 i.v. (0.5 h), days 7, 8, 14, 15; CP 500 mg/m2 i.v.(1 h) day 1;
IDA 8 mg/m2 i.v. (0,5 h), dani 7, 8, 14, 15; CP 500 mg/m2 i.v.(1 h) dan 1;
IDA 8 mg/m2 i.v. (0.5 h), days 7, 8, 14, 15; CP 500 mg/m2 i.v.(1 h) day 1;
IDA 8 mg/m² i.v. (0,5 h), dani 7, 8, 14, 15; CP 500 mg/m² i.v.(1 h) dan 1;
IDA 9 mg/m2 oral, days 1-28;
IDA 9 mg/m2 peroralno, dani 1-28;
IDA 9 mg/m2 oral, days 1-28;
IDA 9 mg/m2peroralno, dani 1-28;
IDA 9 mg/m2 oral, days 1-28;
IDA 9 mg/m² peroralno, dani 1-28;
IDA Business & Technology Park Carrigtohill, County Cork
IDA Business & Technology Park Carrigtohill
IDA Business and Technology Park Carrigtohill
IDA Business i Technology Park Carrigtohill
Idarucizumab was rapidly eliminated with a total clearance of 47.0 mL/min (gCV 18.4 %), an initial half-life of 47 minutes (gCV 11.4 %) and a terminal half-life of 10.3 h (gCV 18.9 %).
Idarucizumab se brzo eliminirao uz ukupni klirens od 47,0 ml/min. (gCV 18,4%), početni poluvijek od 47 minuta (gCV 11,4%) i terminalni poluvijek od 10,3 h (gCV 18,9%).
ide effects caused by the other medicines you are also taking complications of HIV infection.
nuspojava izazvanih drugim lijekovima koje istodobno uzimate komplikacija infekcije HIV-om.
Ideally, pregnancy testing, issuing a prescription and dispensing should occur on the same day.
U idealnom slučaju testiranje na trudnoću trebalo bi obaviti isti dan kada se lijek propisuje i izdaje.
ideation, suicide
ideacija, pokušaj
Idebenone is not a substrate for p-gp in vitro.
Idebenon nije substrat za g-gp in vitro.
IDeg obs. rate
IDeg primij.stopa
IDegLira obs. rate IDegLira
IDegLira primij.stopa IDegLira
Idelalisib exposure may be reduced when co-administered with CYP3A inducers such as rifampicin, phenytoin, St. John’s wort (Hypericum perforatum), or carbamazepine.
Izloženost idelalisibu može biti smanjena ako se primjenjuje istovremeno s CYP3A induktorima kao što su rifampicin, fenitoin, gospina trava (Hypericum perforatum) ili karbamazepin.
Idelalisib has not been studied in patients with chronic active hepatitis including viral hepatitis.
Idelalisib nije ispitan u pacijenata s kroničnim aktivnim hepatitisom, uključujući virusni hepatitis.
Idelalisib induced lymphoid depletion in spleen, thymus, lymph nodes and gut-associated lymphoid tissue.
Idelalisib uzrokuje limfocitnu depleciju u slezeni, timusu, limfnim čvorovima i limfnom tkivu u crijevu.
Idelalisib inhibits phosphatidylinositol 3-kinase p110δ (PI3Kδ), which is hyperactive in B-cell malignancies and is central to multiple signalling pathways that drive proliferation, survival, homing, and retention of malignant cells in lymphoid tissues and bone marrow.
Idelalisib inhibira fosfatidil-inozitol-3-kinazu p110δ (PI3Kδ), koja je pretjerano aktivna u zloćudnim tumorima B-stanica i ključna u brojnim signalnim putevima koji pokreću proliferaciju, preživljavanje, naseljavanje i zadržavanje zloćudnih stanica u limfnom tkivu i koštanoj srži.
Idelalisib is a selective inhibitor of adenosine-5’-triphosphate (ATP) binding to the catalytic domain of PI3Kδ, resulting in inhibition of the phosphorylation of the key lipid second messenger phosphatidylinositol and prevention of Akt (protein kinase B) phosphorylation.
Idelalisib je selektivni inhibitor vezanja adenozin-5’-trifosfata (ATP-a) na katalitičku domenu PI3Kδ, čime se inhibira fosforilacija fosfatidil-inozitola, ključnog lipidnog drugog glasnika, i sprečava fosforilacija kinaze Akt (protein kinaze B).
Idelalisib should not be co-administered with alfuzosin.
Idelalisib se ne smije istovremeno primjenjivati s alfuzosinom.
Idelalisib should not be co-administered with cisapride.
Idelalisib se ne smije istovremeno primjenjivati s cisapridom.
Idelalisib should not be co-administered with ergotamine or dihydroergotamine.
Idelalisib se ne smije istovremeno primjenjivati s ergotaminom ili dihidroergotaminom.
Idelalisib should not be co-administered with quetiapine or pimozide.
Idelalisib se ne smije istovremeno primjenjivati s kvetiapinom ili pimozidom.
IDELVION (INN: albutrepenonacog alfa) is a recombinant coagulation factor IX.
IDELVION (INN: albutrepenonakog alfa) je rekombinantni koagulacijski faktor IX.
IDELVION 1000 IU powder and solvent for solution for injection 1 vial with powder
IDELVION 1000 IU prašak i otapalo za otopinu za injekciju 1 bočicu s praškom
IDELVION 1000 IU powder and solvent for solution for injection 260 – 300 mOsm/kg.
IDELVION 1000 IU prašak i otapalo za otopinu za injekciju 260 – 300 mOsm/kg.
IDELVION 1000 IU powder and solvent for solution for injection 3 years
IDELVION 1000 IU prašak i otapalo za otopinu za injekciju 3 godine
IDELVION 2000 IU powder and solvent for solution for injection 1 vial with powder
IDELVION 2000 IU prašak i otapalo za otopinu za injekciju 1 bočicu s praškom
IDELVION 2000 IU powder and solvent for solution for injection 260 – 300 mOsm/kg.
IDELVION 2000 IU prašak i otapalo za otopinu za injekciju 260 – 300 mOsm/kg.
IDELVION 2000 IU powder and solvent for solution for injection 3 years
IDELVION 2000 IU prašak i otapalo za otopinu za injekciju 3 godine
IDELVION 250 IU powder and solvent for solution for injection 175 – 215 mOsm/kg.
IDELVION 250 IU prašak i otapalo za otopinu za injekciju 175 – 215 mOsm/kg.
IDELVION 250 IU powder and solvent for solution for injection 2 years
IDELVION 250 IU prašak i otapalo za otopinu za injekciju 2 godine
IDELVION 250 IU powder and solvent for solution for injection: 1 vial with powder
IDELVION 250 IU prašak i otapalo za otopinu za injekciju: 1 bočicu s praškom
IDELVION 500 IU powder and solvent for solution for injection 1 vial with powder
IDELVION 500 IU prašak i otapalo za otopinu za injekciju: 1 bočicu s praškom
IDELVION 500 IU powder and solvent for solution for injection 2 years
IDELVION 500 IU prašak i otapalo za otopinu za injekciju 2 godine
IDELVION 500 IU powder and solvent for solution for injection 260 – 300 mOsm/kg.
IDELVION 500 IU prašak i otapalo za otopinu za injekciju 260 – 300 mOsm/kg.
IDELVION does not effect your ability to drive and use machines.
IDELVION ne utječe na sposobnost upravljanja vozilima i rada sa strojevima.
IDELVION is a haemophilia medicine that replaces a natural blood clotting (coagulation) factor IX.
IDELVION je lijek za hemofiliju koji zamjenjuje prirodni faktor zgrušavanja (koagulacije) krvi IX.
Idelvion is a medicine used to prevent and treat bleeding in patients with haemophilia B, an inherited bleeding disorder caused by lack of a clotting protein called factor IX.
Idelvion je lijek koji se koristi za sprečavanje i liječenje krvarenja u bolesnika s hemofilijom B, nasljednim poremećajem krvarenja prouzročenim manjkom proteina za zgrušavanje krvi koji se naziva faktor IX.
IDELVION must not be mixed with other medicines or solvents except those mentioned in section 6.
IDELVION se ne smije miješati s drugim lijekovima ili otapalima osim onih navedenih u dijelu 6.
identification and selection of a more targeted population of patients most likely
omogućila identifikacija i odabir više ciljane populacije bolesnika koja će
Identification of treatment area
Utvrđivanje područja liječenja
Identified adverse reactions associated with Aranesp are hypertension, stroke, thromboembolic events, convulsions, allergic reactions, rash/erythema and pure red cell aplasia (PRCA); see section 4.4.
Prepoznate nuspojave povezane s Aranespom su hipertenzija, moždani udar, tromboembolijski događaji, konvulzije, alergijske reakcije, osip/eritem i izolirana aplazija crvenih krvnih stanica (PRCA); vidjeti dio 4.4.
Identify T cell signature from narcoleptic patients by deep sequencing of total CD4 T cells obtained from narcolepsy patients and DQ0602-matched non-vaccinated healthy subjects and, if identified, verify if signature is found in CD4 T cells from healthy subjects after vaccination with Pandemrix or non-adjuvanted H1N1v vaccine.
Identificirati T-stanični genski profil u bolesnika s narkolepsijom dubokim sekvencioniranjem sveukupnih CD4 T stanica dobivenih od bolesnika s narkolepsijom i DQ0602 podudarnih necijepljenih zdravih ispitanika i, ako je identificiran, utvrditi je li genski profil nađen i u CD4 T stanicama zdravih ispitanika nakon cijepljenja s cjepivom Pandemrix ili s neadjuvantiranim cjepivom H1N1v.
IDet (o.d./b.i.d.)2
IDet (j.d./d.d.)2
IDflu 15 µg/strain 2016/2017 Influenza vaccine Intradermal use
IDflu 15 µg/soj 2016/2017 Cjepivo protiv influence Za primjenu u kožu
IDflu has no or negligible influence on the ability to drive and use machines.
IDflu ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada na strojevima.
IDflu is a suspension for injection in a pre-filled syringe of 0.1 ml with a Micro-Injection System in packs of 1, 10 or 20.
IDflu je suspenzija za injekciju u napunjenoj štrcaljki od 0,1 ml s mikroinjekcijskim sustavom u pakovanjima od 1, 10 ili 20.
IDflu is at least as immunogenic as the comparator trivalent inactivated influenza vaccine administered by intramuscular route for each of the 3 influenza strains in subjects from 60 years of age and over.
Kod ispitanika u dobi od 60 godina i starijih u slučaju sva tri soja cjepivo IDflu je u komparaciji s trovalentnim inaktiviranim cjepivom protiv influence koje se primjenjuje intramuskularnim putem pokazalo najmanje istu imunogenost.
IDflu is not recommended for use in children and adolescents below 18 years.
IDflu se ne preporučuje za primjenu u djece i adolescenata mlađih od 18 godina.
IDflu may be given at the same time as other vaccines.
IDflu se može dati istovremeno s drugim cjepivima.
Idiopathic or cyclic neutropenia:
Idiopatska ili ciklička neutropenija:
Idiopathic or cyclic neutropenia: the recommended starting dose is 0.5 MU (5 micrograms)/kg/day as a single dose or in divided doses.
Idiopatska ili ciklička neutropenija: preporučena početna doza je 0,5 MU (5 mikrograma)/kg/dan u jednokratnoj ili podijeljenoj dozi.
Idiopathic or heritable PAH was the most common aetiology in the study population (56%), followed by PAH due to connective tissue disorders (37%), PAH associated with drugs and toxins (3%), corrected simple congenital heart disease (2%), and HIV (2%).
Idiopatski ili nasljedni PAH bio je najčešća etiologija u ispitivanoj populaciji (56%), a nakon njega su slijedili PAH povezan s bolešću vezivnog tkiva (37%), PAH povezan s lijekovima i toksinima (3%), korigirana jednostavna prirođena srčana bolest (2%) i HIV (2%).
Idiopathic or heritable PAH was the most common aetiology in the study population (57%), followed by PAH due to connective tissue disorders (31%), PAH associated with corrected simple congenital heart disease (8%), and PAH associated with other aetiologies (drugs and toxins [3%] and HIV [1%]).
Idiopatski ili nasljedni PAH bio je najčešća etiologija u populaciji ispitivanja (57%), nakon čega je slijedio PAH zbog bolesti vezivnog tkiva (31%), PAH povezan s korigiranom jednostavnom srčanom manom (8%) i PAH povezan s drugim etiologijama (lijekovi i toksini [3%] i HIV [1%]).
Idiopathic or heritable PAH was the most common aetiology in the study population (58%) followed by PAH due to connective tissue disorders (29%), PAH associated with simple corrected congenital heart disease (10%), and PAH associated with other aetiologies (drugs and toxins [2%] and HIV [1%]).
U ispitivanoj populaciji etiološki je najčešći bio idiopatski ili nasljedni PAH (58%), zatim PAH zbog bolesti vezivnog tkiva (29%) PAH povezan s korigiranom jednostavnom prirođenom srčanom manom (10%) te PAH povezan s drugom etiologijom (lijekovi i toksini [2%] i HIV [1%]).
Idiopathic or thrombotic thrombocytop enic purpura
idiopatska ili trombotska trombocito- penijska purpura
idiopathic thrombocytopaenic purpura
idiopatska trombocitopenična purpura
Idiopathic thrombocytopenia, including severe cases
idiopatska trombocitopenija, uključujući teške slučajeve
Idiopathic thrombocytopenic purpura (N)
idiopatska trombocitopenična purpura (N)
Idiopathic thrombocytopenic purpura*, lymphadenopathy*
idiopatska trombocitopenična purpura*, limfadenopatija
Idiosyncratic infusion related reactions
Idiosinkrazijske reakcije povezane s infuzijom
Idursulfase
Idursulfaza
Idursulfase is taken up by selective receptor-mediated mechanisms involving binding to mannose 6- phosphate receptors.
Idursulfaza se preuzima mehanizmom putem selektivnih receptora koji uključuje vezanje na manoza-6- fosfat receptore.
IDV + NRTIs
IDV + NRTI
IEC 60601 test level
Razina ispitivanja prema IEC 60601
IEC 60601 test level *
Razina testa prema IEC 60601
If  and part of the  are in the dose window and the dose knob cannot be pushed in:
Ako su u prozorčiću za doziranje  i dio simbola , a gumb za doziranje se ne može pritisnuti:
If  and part of the are in the dose window and the dose knob cannot be pushed in:
Ako su u prozorčiću za doziranje  i dio simbola , a gumb za doziranje se ne može pritisnuti:
If  is in the dose window and the dose knob will not turn:
Ako je u prozorčiću za doziranje , a gumb za doziranje se ne može okrenuti:
If  is in the dose window:
Ako je u prozorčiću za :